Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2012. The report details a specific share repurchase transaction executed on June 8, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,600,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,447.0 pence per share; lowest price paid was 1,429.0 pence per share.
- Treasury Holdings (Settled): 454,457,927 shares (8.32% of total issued share capital).
- Treasury Holdings (Including Unsettled): 459,557,927 shares (9.17% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,010,658,964 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,600,000 shares for treasury. This transaction increased the percentage of shares held in treasury from the prior settled position to 8.32% of issued capital, and to 9.17% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural announcement regarding share repurchase activity and voting rights calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (454,457,927 settled) against the company's latest capitalization table.
- Confirm the impact of the 9.17% treasury holding on total voting rights for proxy calculations.
- Check the settlement status of the 5,100,000 shares purchased but not yet settled at the time of filing.
- Review the remaining authorization for share buybacks under the mandate granted on May 3, 2012.